See also: Generic Zyprexa, Generic Zyprexa Relprevv
Zyprexa Zydis is a brand name of olanzapine, approved by the FDA in the following formulation(s):
ZYPREXA ZYDIS (olanzapine - tablet, orally disintegrating; oral)
Manufacturer: LILLY
Approval date: April 6, 2000
Strength(s): 10MG [AB], 15MG [AB], 20MG [AB], 5MG [RLD][AB]
Has a generic version of Zyprexa Zydis been approved?
A generic version of Zyprexa Zydis has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zyprexa Zydis and have been approved by the FDA:
olanzapine tablet, orally disintegrating; oral
Manufacturer: APOTEX INC
Approval date: October 24, 2011
Strength(s): 10MG [AB], 15MG [AB], 20MG [AB], 5MG [AB]
Manufacturer: BARR LABS INC
Approval date: January 30, 2012
Strength(s): 10MG [AB], 15MG [AB], 20MG [AB], 5MG [AB]
Manufacturer: DR REDDYS LABS LTD
Approval date: October 24, 2011
Strength(s): 10MG [AB], 15MG [AB], 20MG [AB], 5MG [AB]
Manufacturer: PAR PHARM
Approval date: October 24, 2011
Strength(s): 10MG [AB], 15MG [AB], 20MG [AB], 5MG [AB]
Manufacturer: TORRENT PHARMS LLC
Approval date: October 25, 2011
Strength(s): 10MG [AB], 15MG [AB], 20MG [AB], 5MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zyprexa Zydis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
2-methyl-thieno-benzodiazepine
Patent 5,229,382
Issued: July 20, 1993
Inventor(s): Chakrabarti; Jiban K. & Hotten; Terrence M. & Tupper; David E.
Assignee(s): Lilly Industries Limited
2-Methyl-10-(4-methyl-1-piperazinyl)-4H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##Patent expiration dates:
- October 23, 2011✓
- October 23, 2011
Combination therapy for treatment of refractory depression
Patent 6,960,577
Issued: November 1, 2005
Inventor(s): Tollefson; Gary Dennis
Assignee(s): Eli Lilly and Company
Methods for treating a patient suffering from or susceptible to treatment resistant major depression comprising administering olanzapine and fluoxetine are disclosed.Patent expiration dates:
- November 1, 2017✓
- November 1, 2017
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- March 19, 2012 - TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
- December 4, 2012 - NEW PATIENT POPULATION
- June 4, 2013 - PEDIATRIC EXCLUSIVITY
See also...
- Zyprexa Zydis Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
- Zyprexa Zydis Consumer Information (Cerner Multum)
- Zyprexa Zydis Advanced Consumer Information (Micromedex)
- Olanzapine Consumer Information (Wolters Kluwer)
- Olanzapine Extended-Release Consumer Information (Wolters Kluwer)
- Olanzapine Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
- Olanzapine Tablets Consumer Information (Wolters Kluwer)
- Olanzapine Consumer Information (Cerner Multum)
- Olanzapine injection Consumer Information (Cerner Multum)
- Olanzapine Advanced Consumer Information (Micromedex)
- Olanzapine Intramuscular Advanced Consumer Information (Micromedex)
- Olanzapine AHFS DI Monographs (ASHP)
No comments:
Post a Comment